Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NuVasive Inc is a medical devices business based in the US. NuVasive shares (NUVA) are listed on the NASDAQ and all prices are listed in US Dollars. NuVasive employs 2,900 staff and has a trailing 12-month revenue of around $1.2 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $43.96 |
|---|---|
| 52-week range | $41.33 - $62.83 |
| 50-day moving average | $48.10 |
| 200-day moving average | $51.64 |
| Wall St. target price | $59.92 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.72 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.96 from 2022-10-03
| 1 week (2022-09-28) | -1.08% |
|---|---|
| 1 month (2022-09-02) | 1.41% |
| 3 months (2022-07-05) | -12.71% |
| 6 months (2022-04-05) | -19.78% |
| 1 year (2021-10-05) | -26.71% |
|---|---|
| 2 years (2020-10-05) | -9.58% |
| 3 years (2019-10-04) | 64.52 |
| 5 years (2017-10-05) | 56.46 |
Valuing NuVasive stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NuVasive's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NuVasive's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7855. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NuVasive's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NuVasive's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $193.6 million.
The EBITDA is a measure of a NuVasive's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Operating margin TTM | 4.85% |
| Gross profit TTM | $816.7 million |
| Return on assets TTM | 1.65% |
| Return on equity TTM | -4.81% |
| Profit margin | -3.41% |
| Book value | $15.88 |
| Market capitalisation | $2.3 billion |
TTM: trailing 12 months
We're not expecting NuVasive to pay a dividend over the next 12 months.
Over the last 12 months, NuVasive's shares have ranged in value from as little as $41.33 up to $62.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuVasive's is 1.1786. This would suggest that NuVasive's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NuVasive, Inc. , a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
